Orion Oyj
XMUN:OFK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Orion Oyj
XMUN:OFK
|
FI |
Orion Oyj
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and sells medicines for people and animals. Its main products include prescription drugs, over-the-counter medicines, and veterinary medicines, with a strong focus on treatments for the central nervous system, cancer care, and animal health. The company also makes active pharmaceutical ingredients and other drug-related products that it sells to partners in the healthcare industry. Orion sells its products to pharmacies, hospitals, doctors, veterinarians, and other drug companies. It earns money mainly by selling branded medicines, generic medicines, and pharmaceutical ingredients, plus royalties and license income from drug development partnerships. In practice, Orion sits between research and the end market: it turns drug research and manufacturing know-how into finished medicines that can be sold under its own brands or by partners. What makes Orion different is its mix of human health, animal health, and drug ingredient businesses under one roof. That gives it multiple ways to make money from the same scientific and manufacturing base, while reducing reliance on any single product line. For beginner investors, the key point is that Orion is not a broad healthcare company; it is a focused drug maker that competes through pharmaceutical research, regulatory expertise, and reliable production.
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and sells medicines for people and animals. Its main products include prescription drugs, over-the-counter medicines, and veterinary medicines, with a strong focus on treatments for the central nervous system, cancer care, and animal health. The company also makes active pharmaceutical ingredients and other drug-related products that it sells to partners in the healthcare industry.
Orion sells its products to pharmacies, hospitals, doctors, veterinarians, and other drug companies. It earns money mainly by selling branded medicines, generic medicines, and pharmaceutical ingredients, plus royalties and license income from drug development partnerships. In practice, Orion sits between research and the end market: it turns drug research and manufacturing know-how into finished medicines that can be sold under its own brands or by partners.
What makes Orion different is its mix of human health, animal health, and drug ingredient businesses under one roof. That gives it multiple ways to make money from the same scientific and manufacturing base, while reducing reliance on any single product line. For beginner investors, the key point is that Orion is not a broad healthcare company; it is a focused drug maker that competes through pharmaceutical research, regulatory expertise, and reliable production.
Results: Orion said Q1 was solid across all businesses, with net sales up almost 18%, operating profit up 47%, and EPS up 47%.
Nubeqa: Innovative Medicines was the main growth engine, driven by Nubeqa royalties and tablet sales; management said Q1 was still below Q4 because royalties are tiered through the year and March estimates are updated later.
Guidance: Orion raised the lower end of its full-year outlook by EUR 50 million for both net sales and operating profit after a strong first quarter and slightly lower downside risk from potential U.S. pharma tariffs.
Pipeline: Orion highlighted two pipeline updates: FDA orphan drug designation for ODM-212 in mesothelioma and the start of the TEADCO Phase Ib/II combination study.
Outlook: Management said it expects higher Nubeqa tablet deliveries later in the year, but warned that quarterly tablet shipments are not a reliable guide to future sales or inventory levels.
